Cover Image
市場調查報告書

多發性骨髓瘤

Multiple myeloma

出版商 Datamonitor Healthcare 商品編碼 365183
出版日期 內容資訊 英文 367 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性骨髓瘤 Multiple myeloma
出版日期: 2016年04月01日 內容資訊: 英文 367 Pages
簡介

本報告提供多發性骨髓瘤的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,患病人數的增加要素,及目前代表性產品,開發中產品的上市給予市場的影響,主要產品 (Revlimid、Velcade)的一般化帶給今後的市場規模的影響,美國、日本、歐洲的代表性產品,殘留的未滿足需求等相關調查。

市場預測:多發性骨髓瘤

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Darzalex (Daratumumab)
  • Empliciti (Elotuzumab)
  • Farydak (Panobinostat)
  • Keytruda (pembrolizumab)
  • Kyprolis (carfilzomib)
  • Ninlaro (ixazomib)
  • Pomalyst (pomalidomide)
  • Revlimid (lenalidomide)
  • Selinexor
  • Thalomid (thalidomide)
  • Velcade (bortezomib)
  • 一次調查技術

治療方法:多發性骨髓瘤

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢

流行病學:多發性骨髓瘤

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:多發性骨髓瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Darzalex
  • 產品簡介:Empliciti
  • 產品簡介:Farydak
  • 產品簡介:Kyprolis
  • 產品簡介:Ninlaro
  • 產品簡介:Pomalyst
  • 產品簡介:Revlimid
  • 產品簡介:Thalomid
  • 產品簡介:Velcade

開發中產品:多發性骨髓瘤

  • 摘要整理
  • 臨床實驗開發平台概要
  • 目標產品簡介
  • 臨床實驗的設計
  • 最近,臨床實驗中止的藥物
  • 產品簡介 (最後階段):Aplidin
  • 產品簡介 (最後階段):Keytruda
  • 產品簡介 (最後階段):selinexor

附錄

  • 附錄:多發性骨髓瘤的流行病學

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5921

Despite genericization of key brands, the multiple myeloma market is expected to continue to grow due to new product launches, label expansions, and rising disease prevalence.

This report addresses the following questions:

  • What factors are contributing to the increase in prevalence of multiple myeloma?
  • Which brands are the current market leaders in multiple myeloma?
  • What impact will the approvals of pipeline therapies have on treatment patterns?
  • How will genericization of Revlimid and Velcade impact the value of the overall lmarket over the forecast period?
  • What are the most popular drug treatment regimens by patient segment in the US, Japan, and five major EU markets?
  • In what patient population does there remain an unmet treatment need?

TABLE OF CONTENTS

FORECAST: MULTIPLE MYELOMA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Darzalex (daratumumab)
  • 5. Empliciti (elotuzumab)
  • 6. Farydak (panobinostat)
  • 7. Keytruda (pembrolizumab)
  • 8. Kyprolis (carfilzomib)
  • 9. Ninlaro (ixazomib)
  • 10. Pomalyst (pomalidomide)
  • 11. Revlimid (lenalidomide)
  • 12. Selinexor
  • 13. Thalomid (thalidomide)
  • 14. Velcade (bortezomib)
  • 15. Primary Research Methodology

TREATMENT: MULTIPLE MYELOMA

  • 16. Executive Summary
  • 17. Primary Research Methodology
  • 18. Disease Definition and Diagnosis
  • 19. Patient Segmentation
  • 20. Country Treatment Trees
  • 21. Current Treatment Options
  • 22. Prescribing Trends

EPIDEMIOLOGY: MULTIPLE MYELOMA

  • 23. Executive Summary
  • 24. Disease Background
  • 25. Sources and Methodology Forecast
  • 26. Epidemiologist Insight
  • 27. Strengths and Limitations

MARKETED DRUGS: MULTIPLE MYELOMA

  • 28. Executive Summary
  • 29. Product Overview
  • 30. Product profile: Darzalex
  • 31. Product profile: Empliciti
  • 32. Product profile: Farydak
  • 33. Product profile: Kyprolis
  • 34. Product profile: Ninlaro
  • 35. Product profile: Pomalyst
  • 36. Product profile: Revlimid
  • 37. Product profile: Thalomid
  • 38. Product profile: Velcade

PIPELINE: MULTIPLE MYELOMA

  • 39. Executive Summary
  • 40. Clinical Pipeline Overview
  • 41. Target Product Profile
  • 42. Clinical Trial Design
  • 43. Recently Discontinued Drugs
  • 44. Product profile (late stage): Aplidin
  • 45. Product profile (late stage): Keytruda
  • 46. Product profile (late stage): selinexor

APPENDIX

  • 47. Appendix: Epidemiology: Multiple Myeloma
Back to Top